Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Babies born very prematurely will be offered protection against respiratory syncytial virus (RSV) with a long-acting antibody ...

Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...

London: A new study has shown that vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a ...

A major UK study has revealed that vaccinating pregnant women against respiratory syncytial virus (RSV) has led to a 72% reducti ...

Thousands of at-risk infants – including those born prematurely in Andover and across Hampshire – will receive long-lasting ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...

The first sign of multiple myeloma varies by person and may not occur until a later stage of the disease. Learn how to ...

French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...